T increase was insignificant (<71) but that ofnand OHP was noted (76. 102). Among lo male pseudThermaphrodites (MPH) 6 had normal T, 4, OHP response, 4 had low T (155?68) but normal for agehincrease after HCG (59'14) .
In 6 cases of Morris' sd HCG response was normal or high. Fluoxymesterone significantly decreased T, A .
OHP in 7 cases. It is suggested that prepubertal testis can contribute t o h , OHP plasma pool. Since 2 weeks of HCG stimulation led to male adult levels for T and OHP but not forband since cortisol secretion does not vary with age, a change in adrenal androgen biosynthesis would occur during sexual maturation. In undescended testis as EIPH with low T, but normal Aresponse to HCG. an abnormal T biosynthesis might exist beside a relative testicular deficiency.
EFFECTS OF SOMATOSTATIN ON PLASMA INSULIN, GROIJTH

HORMONE AND GLUCAGON LEVELS IN OBESE AND DIABETIC
CHILDREN AND ADOLESCENTS. L. Gargantini and G.Chiumello, Dept. of Pediatrics, University of Milan, Italy.
Somatostatin (GHRIH) could be helpful in the treatment of diabetes mellitus when high levels of growth hormone and glucagon interfere with the metabolic control. In obese children the i.v. injection of 3 ug/kg of ideal body weight of GHRIH before i.v. glucose tolerance test lowered significantly the glucose disappearance rate, the plasma insulin levels, and delayed the peak value. In diabetic children the i.v. administration of 3 ,ug/kg of GHRIH over two min, followed by a 60 min infusion of 7 pg/kg in saline solution induced a significant decrease of blood sugar, growth hormone and glucagon levels; the administration of 3 pglkg of GHR-IH immediately before a standardized physical exertion significantly reduced the rise of growth hormone levels. GHRIH can open new possibilities in the treatment of juvenile diabetes, at least after puberty.
McCUNE-ALBRICHT's SYN. IN A MALE CHILD: A CLINICAL-
19 ENDOCRINOLOGICAL PUZZLE. G.Ciovannelli, S. Rernasconi and G.Ranchini, Dept. of Pediat., Univ. of Parma,Italv A 6 112 yr old hoy shows a combination of polyostotic fibrous dvsplasia, sclerosis of the base of the skulli "cafi-au-lait" spots and enlarged testes (12115 mls). Histological examination, at biopsy, displays a pattern of mature testicular tissue with spermatogenesis. No presence of secondarv sex characteristics. No advanced bone age. Height: 90th percentile. Plasma testosterone at upper limits of prepubertal ranae. After Gn-RlI stimulation FSH fails to rise, whereas LH response may still be considered within normal. GH and cortisol after insuline tolerance test normal. No rise of TSH elicited after TRH, while prolactin increases normally. No uptake of 131-1 in a large area of the right lobe of thvroid (scanning) neither before nor after TSH stimulation. Normal plasma T4 and T3 (RIA). The gathered data substantiate the presence of pluriglandular involvement, the pathogenesis of which still appears uncertain. Patients treated with Cyproteronacetate in a daily dose of 75 mgl m2 complained of striking fatigue at the beginning of treatment. Random plasma-cortisol-concentrations were unmeasurable (< 1 ug%) and simultaneous plasma-ACTH-concentrations were also below the sensitivity of the assay (30-50 pg/ml).DXminishedexcretion of free cortisol in 24 h-urine and depressed plasma-cortisol-response to exogenousACTH. -A partial secondary adrenal insufficiency was thus suspected and the following investigation performed in Albino Rats: daily treatment with Cyproteronacetate (3 nglloog) over 16 days. Blood was then collected in EDTA on ice and centrifuged at 4O C, plasma-aliquots frozen at -20°C for corticosterone and ACTHassays. Results showed lowered to unmeasurable corticosteroneconcentrations (mean 3,9 gamma%) in treated rats as compared to controls (23,s gama%). The mean ACTH-concentration in treated rats was 580 pg/ml as compared to 1'525 pglml plasma in controls. A further series of experiments showed dose and duration of Cyproteronacetate-treatment required to induce secondary adrenal insufficiency in rats. The effect of simultaneous intermittent ACTH-treatment elucidates the indication for such a concomitant therapy in Cyproteronacetate-treated children with precocious puberty. 53 boys with a mean testosterone treatment (tt) period of 1.1 yrs were studied. Testicular volume (tv) was analyzed in 33 during a posttherapeutic period of 1.5 vrs or more. Sperm counts were done in 25 and LHRB test in 19 at different intervals after tt. Mean tv was 7.2'2.8 ml (-2.1 SD for bone age 17) at the end of tt and 14.724.5 ml (-0.5 SD for bone age 17, the lowest value being -1.9 SD) after a mean post-therapeutic period of 2.0 yrs. Sperm count was above 25xl0~/ml after a mean period of 1.9 yrs (0.5-5.9 yrs) in 22 boys. The velocity of testicular catch-up growth and of normalisation of sperm count showed great individual variation. In 3 boys with normal tv sperm counts were not yet normal after 1.3-2.9 yrs. There was no correlation between tv and sperm count and between tv or sperm count and duration of tt. LH and FSH values before and after LHRH were low during and at the end of tt, but became normal within a few months. It is concluded that testicular function is suppressed during tt and recovers in general within 2 years.
PRIMARY ADRENAL INSUFFICIENCY AND PRECOCIOUS PUBERTY
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